Pmv Pharmaceuticals, Inc. PMVP
We take great care to ensure that the data presented and summarized in this overview for PMV Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PMVP
View all-
Orbimed Advisors LLC San Diego, CA6.48MShares$13.9 Million0.25% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.2MShares$6.88 Million0.07% of portfolio
-
Black Rock Inc. New York, NY3.11MShares$6.69 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY2.63MShares$5.65 Million0.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.45MShares$5.27 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY2.35MShares$5.04 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA2.08MShares$4.47 Million0.01% of portfolio
-
Interwest Venture Management CO1.61MShares$3.47 Million48.05% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.58MShares$3.4 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.37MShares$2.94 Million0.0% of portfolio
Latest Institutional Activity in PMVP
Top Purchases
Top Sells
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Insider Transactions at PMVP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 18
2024
|
Deepika Jalota Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,555
+43.23%
|
-
|
|
Jan 18
2024
|
David Henry Mack President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
163,890
+27.03%
|
-
|
|
Jan 18
2024
|
Michael Carulli Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,220
+47.39%
|
-
|
|
Nov 22
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
87,786
-100.0%
|
$175,572
$2.23 P/Share
|
|
Nov 10
2023
|
David Henry Mack President and CEO |
BUY
Bona fide gift
|
Indirect |
85,307
+34.04%
|
-
|
|
Nov 10
2023
|
David Henry Mack President and CEO |
SELL
Bona fide gift
|
Direct |
85,307
-23.44%
|
-
|
|
Oct 18
2023
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
198,407
+35.29%
|
$0
$0.53 P/Share
|
|
Sep 15
2023
|
Deepika Jalota Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,104
-12.05%
|
$24,624
$6.62 P/Share
|
|
Sep 15
2023
|
Leila Alland Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,291
-12.05%
|
$37,746
$6.62 P/Share
|
|
Aug 07
2023
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
85,500
+34.07%
|
$0
$0.53 P/Share
|
|
Nov 25
2022
|
Winston Kung COO, CFO |
SELL
Bona fide gift
|
Direct |
2,560
-19.45%
|
-
|
|
Sep 09
2022
|
Deepika Jalota Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,050
+50.0%
|
-
|
|
Sep 09
2022
|
Leila Alland Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,200
+50.0%
|
-
|
|
May 26
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,253
-23.02%
|
$393,795
$15.93 P/Share
|
|
Apr 27
2022
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,000
+29.21%
|
$0
$0.53 P/Share
|
|
Apr 20
2022
|
Winston Kung COO, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+27.4%
|
$12,000
$3.22 P/Share
|
|
Mar 31
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,500
-100.0%
|
$724,500
$21.17 P/Share
|
|
Mar 30
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
75,000
-68.49%
|
$1,650,000
$22.39 P/Share
|
|
Mar 29
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
365,000
-76.92%
|
$7,665,000
$21.52 P/Share
|
|
Mar 08
2022
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+29.86%
|
$20,000
$1.37 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 342K shares |
|---|---|
| Bona fide gift | 85.3K shares |
| Exercise of conversion of derivative security | 284K shares |
| Open market or private sale | 98.2K shares |
|---|---|
| Bona fide gift | 85.3K shares |